Femasys Inc (FEMY)
Official siteHEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • NASDAQ
Market Cap: $11.89M
Last updated: Nov 17, 2026 at 4:15 PM ET
Femasys Inc (FEMY) Statistics
Femasys (FEMY) has a market cap of $11.89M. Its share count is up 8346.02% from a year earlier. It kept -614.68% of revenue as net income over the last 12 months.
Total Valuation
| Market Cap | $11.89M |
|---|---|
| Latest price (Nov 17, 2026) | $1.12 |
Key Dates
The next earnings report is expected on Mar 29, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 29, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 13, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 4.9x and 0.4x. Its year-end P/S ranged from 8.8x to 443.8x from 2021 to 2025.
| P/S Ratio | 4.9x |
|---|---|
| Forward P/S | 5.7x |
| P/B Ratio | 0.4x |
| P/TBV Ratio | 0.4x |
Price Statistics
The stock is down 93.76% over 52 weeks and trades 40.74% below its 50-day average.
| Beta (1Y) | 1.99 |
|---|---|
| 52-Week Change | -93.76% |
| 1-Month Change | -31.29% |
| 3-Month Change | -58.67% |
| 6-Month Change | -84.38% |
| 5-Year Change | -99.01% |
| Total Return (1Y) | -93.76% |
| Total Return (3Y CAGR) | -61.27% |
| Total Return (5Y CAGR) | -59.48% |
| Return vs SPY (1Y) | -103.78% |
| Max Drawdown (1Y) | -94.46% |
| Max Drawdown (3Y) | -97.48% |
| Sharpe Ratio (1Y) | -2.58 |
| Correlation with SPY (1Y) | 0.27 |
| 50-Day Average | $1.89 |
| 200-Day Average | $5.49 |
| 52-Week Range | $1.25 to $20.80 |
| RSI (14 Days) | 29.3 |
| Average Volume (20 Days) | 107.08K |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 8.67x current liabilities, and total debt is 0.15x shareholder equity.
| Current Ratio | 8.67x |
|---|---|
| Quick Ratio | 6.95x |
| Debt / Equity | 0.15x |
| Interest Coverage | -12.77x |
Returns and Efficiency
Return on invested capital is -39.96% and return on equity is -44.91% over the last 12 months.
| Return on Equity (ROE) | -44.91% |
|---|---|
| Return on Assets (ROA) | -34.59% |
| Return on Invested Capital (ROIC) | -39.96% |
| ROA (5Y Average) | -77.25% |
| Asset Turnover | 0.08x |
| Inventory Turnover | 0.13x |
| Receivables Turnover | 10.26x |
| Cash Conversion Cycle | 1894 days |
Scores
FEMY has an Altman Z-Score of -5.59, in the distress zone below 1.81, and a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -5.59 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 2 of 9 |
| Piotroski Strength | Weak |
Income Statement
Revenue of $1.97M over the last 12 months is down 4.21% from the 12 months before.
| Revenue | $1.97M |
|---|---|
| Revenue Growth (YoY) | -4.21% |
| Gross Profit | $1.18M |
| Operating Income | -$18.36M |
| Pretax Income | -$12.13M |
| Net Income | -$12.14M |
| EBITDA | -$10.83M |
| Reported EPS (TTM) | -$3.52 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 77.03% of the $35.09M in total assets.
| Cash and Equivalents | $23.91M |
|---|---|
| Total Debt | $4.01M |
| Net Cash | $19.90M |
| Net Cash Per Share | $2.30 |
| Working Capital | $27.61M |
| Shareholder Equity | $27.03M |
| Book Value Per Share | $3.12 |
| Tangible Book Value | $26.93M |
| Tangible Book Per Share | $3.11 |
| Total Assets | $35.09M |
| Total Liabilities | $8.06M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $245.89K of capital spending, operating cash flow left -$17.33M of free cash flow.
| Operating Cash Flow | -$17.08M |
|---|---|
| Capital Expenditures | $245.89K |
| Free Cash Flow | -$17.33M |
| FCF Per Share | -$2.07 |
| Depreciation and Amortization | $1.57M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -929.87%.
| Gross Margin | 59.91% |
|---|---|
| Operating Margin | -929.87% |
| Pretax Margin | -614.36% |
| Net Margin | -614.68% |
| EBITDA Margin | -548.68% |
| FCF Margin | -877.49% |
| Gross Margin (5Y Average) | 65.00% |
Growth
Revenue grew 23.88% a year over 3 years.
| Revenue Growth (3Y CAGR) | +23.88% |
|---|---|
| Revenue Growth (5Y CAGR) | +17.18% |
Dividends and Yields
FEMY does not pay a dividend. Its free cash flow yield is -178.64%.
| FCF Yield | -178.64% |
|---|---|
| Buyback Yield | -301.56% |
| Shareholder Yield | -301.56% |
Stock Splits
The last split was a 1-for-20 reverse split on Jun 8, 2026.
| Last Split Date | Jun 8, 2026 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:20 |
Peer Position
Against 10 similar companies, FEMY has the 4th highest P/S.
P/S RatioPeer median 2.7x
ROICPeer median 6.96%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +3.93%
| P/S Ratio | 4.9x vs 2.7x median |
|---|---|
| ROIC | -39.96% vs 6.96% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | -4.21% vs +3.93% median |
Analyst Forecast
Consensus estimates put revenue growth at 102.86% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +102.86% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About FEMY
What is FEMY's market cap?
Femasys has a market cap of $11.89M.
How many shares of FEMY are outstanding?
Femasys has 8.66M shares outstanding. The count is up 8346.02% from a year earlier.
Does FEMY pay a dividend?
No. Femasys does not pay a dividend.
How much debt does FEMY have?
Femasys has $4.01M of total debt and $23.91M of cash and equivalents, a net cash position of $19.90M.
FEMY pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors